Valtorcitabine Dihydrochloride

泛托西他滨

Report date: 2022/12/07 17:52:31
NME

Base Information

Drug NameValtorcitabine Dihydrochloride
Drug Alias NameValtorcitabina伐托他滨盐酸伐托他滨ValtorcitabinumNM-147 +[7] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHBV DNA Polymerase inhibitors
TargetsHBV DNA Polymerase
Therapy Area/IndicationsHepatitis B, ChronicHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingaporeNew ZealandHong Kong +[4] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesIdenix PharmaceuticalNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma AgPatheon Uk LtdIdenix Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsHepatitis B, ChronicHepatitis B

Other Information

ATC CodeN/A
Related LinksKEGG